Why the study?
Evidence comparing the efficacy and safety of potent P2Y12 inhibitors with clopidogrel is limited in patients with acute myocardial infarction complicated by cardiogenic shock.
Does the use of potent P2Y12 inhibitors reduce major adverse cardiovascular events compared with clopidogrel in patients with acute myocardial infarction complicated by cardiogenic shock?
Population
1482 patients with AMI and cardiogenic shock undergoing culprit-vessel PCI
Comparison
Potent P2Y12 inhibitors vs clopidogrel
Design
Nationwide pooled registry study
Follow-up
2 years
Authors
Loading...
May support potent P2Y12 use except age ≥75 or VA-ECMO; leaves open randomized confirmation before practice change.
Does the use of potent P2Y12 inhibitors reduce major adverse cardiovascular events compared with clopidogrel in patients with acute myocardial infarction complicated by cardiogenic shock?
In patients with acute myocardial infarction complicated by cardiogenic shock, potent P2Y12 inhibitors were associated with a lower risk of MACE compared to clopidogrel without an overall increase in major bleeding, though bleeding risk was elevated in the elderly and those on VA-ECMO.
Jo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: